Middle East & Africa Clinical Trials Market

Middle East and Africa Clinical Trials Market Size (2024 to 2029)

The clinical trials market size in Middle East and Africa was valued at USD 1.57 Billion in 2023. The EA market is projected to reach USD 2.43 Billion by 2029 from USD 1.69 billion in 2024, growing at a CAGR of 7.55% during the forecast period.

The Middle East clinical trial market can be seen as a new opportunity for investment. The emergence of advanced technology is leveling up the growth rate of the market. There is a highly qualified and skilled workforce available in these countries, which is propelling market growth. The government also provides funds for clinical trials. An increasing number of clinical trials due to rising cases of COVID-19 is one of the factors driving the market. There are many local CROs in this region which carry out clinical trials. The University of Baghdad has launched clinical trials for COVID–19 using Ivermectin in the Middle East. This is the key factor that is propelling the market growth in the Middle East.  

The ratio of a clinical trial carried out in the African region is uneven. The funding provided in these countries is also uneven. South Africa invests more in clinical trials than other African countries. There is no proper healthcare infrastructure in most African countries. These are some challenges faced by the clinical trial market in Africa. The healthcare regulatory bodies in Africa are collaborating to conduct clinical trials for COVID-19.   

The Middle East and Africa market for clinical trials is mainly driven by alliances between pharma-biotech companies and clinical research organizations, increasing demand for clinical development outsourcing and innovative solutions in the healthcare industry. Excessive R&D investment in the healthcare industry, the risen prevalence of chronic diseases, increased outsourcing of clinical research and implementation of clinical trials by contract research organizations, and assimilation of clinical trial management systems with hospital information systems are key parameters promoting market growth. A consequent rise in clinical trials in these countries should be associated with high population growth, demand for drugs, and increased incidence of lifestyle-linked and unusual genetic diseases in MEA countries.

However, the market growth can be hampered due to the emerging shortage of clinical resources, such as a lack of disease population, well-trained labor, and sound medical infrastructure, which is delaying the process of initiating trials.

This report on the Middle East and Africa clinical trials market has been segmented into the following categories.

Middle East and Africa Clinical Trials Market - By Phase:

• Phase I
• Phase II
• Phase III

Middle East and Africa Clinical Trials Market – By Design:

• Interventional Trials
• Observational Trials
• Expanded Access Trials

Middle East and Africa Clinical Trials Market - By Indications:

• Autoimmune
• Blood disorders
• Cancer
• Circulatory
• CNS
• Congenital
• CVS
• Dermatology
• Ear
• Gastrointestinal
• Genitourinary
• Infections
• Mental disorders,
• Metabolic
• Musculoskeletal
• Nose
• Ophthalmology

Middle East and Africa Clinical Trials Market – By Country:

• KSA
• UAE
• Israel
• Rest of the GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• Rest of MEA

Geographically, the Clinical Trials market in the Middle East and Africa region is projected to grow at a high CAGR. Emerging countries account for the largest share due to support from the respective government bodies and the growing trend of rising strategic alliances, joint ventures, and acquisitions of qualified investigators, all without the competition or cost they face in more developed nations.

KEY MARKET PARTICIPANTS:

Companies playing a prominent role in the Middle East and Africa clinical trials market profiled in this report are Chiltern, Omnicare, PPD, Parexel, Kendle, Quintles, ICON Plc, and Charles River.